DHR Danaher Corporation
Intrinsic value$47.28
Price (at call)$207.66
Margin of safety
-77.2%
vs market (rating basis)
-48.1%
Model unavailable; showing baseline valuation.
⚠ LLM error: empty response; using baseline
The story
Value drivers
| Revenue growth (Y1) | -2.7% |
| Terminal growth | 3.5% |
| Forecast horizon | 10y |
| Target operating margin | 20.1% |
| Years to target margin | 5 |
| Sales-to-capital | 0.50 |
| Beta | 0.81 |
| Failure probability | 0.0% |
| Cost of capital (WACC) | 8.1% |
| Terminal WACC | 8.9% |
Valuation bridge
| PV of explicit FCFF | 24.91B |
| PV of terminal value | 23.80B |
| Equity value | 33.24B |
| ÷ shares → per share | $47.28 |
News
neutral -0.10 · 8 articles
- Is Revvity Stock a Buy as Growth Improves but Valuation Stays Rich?
- Pediatrix Medical Group (MD) Up 3.4% Since Last Earnings Report: Can It Continue?
- Danaher (DHR) Seen Deftly Navigating AI Integration
- Danaher (DHR) Stock Trades Near Fair Value But At An Earnings Premium
- Merck KGaA shares rise 1.7% after HSBC upgrades stock to Buy
- Is Danaher Stock Underperforming the Nasdaq?
- Jim Cramer Calls BillionToOne (BLLN) a “Pretty Darn Good Company”
- Why Danaher (DHR) Remains a Healthcare Compounder to Watch
Projected free cash flow to the firm
| Yr | Revenue | Growth | Margin | NOPAT | Reinvest | FCFF | PV |
|---|---|---|---|---|---|---|---|
| 1 | 24.44B | -2.7% | 20.1% | 4.18B | 0 | 4.18B | 3.87B |
| 2 | 23.95B | -2.0% | 20.1% | 4.10B | 0 | 4.10B | 3.51B |
| 3 | 23.64B | -1.3% | 20.1% | 4.05B | 0 | 4.05B | 3.20B |
| 4 | 23.50B | -0.6% | 20.1% | 4.02B | 0 | 4.02B | 2.94B |
| 5 | 23.52B | 0.1% | 20.1% | 4.03B | 34.85M | 3.99B | 2.70B |
| 6 | 23.69B | 0.8% | 20.1% | 4.06B | 357.12M | 3.70B | 2.31B |
| 7 | 24.04B | 1.4% | 20.1% | 4.11B | 684.53M | 3.43B | 1.98B |
| 8 | 24.55B | 2.1% | 20.1% | 4.20B | 1.02B | 3.18B | 1.70B |
| 9 | 25.24B | 2.8% | 20.1% | 4.32B | 1.38B | 2.94B | 1.45B |
| 10 | 26.12B | 3.5% | 20.1% | 4.47B | 1.77B | 2.71B | 1.24B |